iRhythm TechnologiesIRTC

iRhythm reported revenue of about 224 million dollars for the quarter, a 20 percent increase over the same time last year. The company also narrowed its net loss to nearly zero, a significant improvement from the 14 million dollar loss it posted a year ago. This progress shows the business is successfully scaling its heart-monitoring platform while keeping costs under control.

Management also raised its financial goals for the full year. It now expects revenue to reach as high as 890 million dollars and adjusted EBITDA margins, a measure of cash profit before certain costs like interest and taxes, to hit 13 to 14 percent. This is a key signal for long-term owners that the company is successfully shifting from a money-losing startup into a profitable medical technology business.

See the full quarter, and how our tracked metrics did

Source: 8-K filing

iRhythm filed a notice with regulators regarding a change to its board of directors or executive leadership team. These filings are required when a company adds or loses a key leader who helps set the business strategy.

While the filing confirms a leadership shift, it does not change the company's current financial targets. For a company like iRhythm that is trying to move from high growth into steady profitability, leadership stability is important to keep its expansion into new markets on track.

Source: 8-K filing

SEC filing on 2026-08-06: 8-K, 8-K filing: entered a material agreement; reported results; Regulation FD disclosure.

Source: 8-K filing

SEC filing on 2026-08-06: 8-K, 8-K filing: entered a material agreement.

Source: 8-K filing

The company is scheduled to share its second quarter results after the market closes today. Analysts expect a loss of about 4 cents per share on revenue of roughly 220 million dollars.

Beyond the top-line numbers, the focus remains on whether the company is maintaining its pace toward full-year profitability. We are watching for updates on the rollout of its newer Zio heart monitors and any progress in clearing its outstanding warning letter from the FDA, the agency that regulates medical devices.

See the full quarter, and how our tracked metrics did

Key highlights

• Profitability outlook improved: Management raised its full year guidance for adjusted EBITDA margin, a measure of core profitability, to a range of 13.0% to 14.0% following a strong quarter. The company also boosted its revenue target for the year to between $880 million and $890 million as demand for heart monitoring stays high.
• Core margins expanding: Gross margin reached 72.8% this quarter, which is a 160 basis point improvement over the same time last year. The company is becoming more efficient at delivering its Zio services as it reaches a larger scale.
• Major acquisition announced: The company agreed to buy VitalConnect for $287.5 million to add new wearable technologies to its cardiac monitoring lineup. This deal aims to expand the number of patients the company can serve and help it move into more parts of the hospital.
• Cost savings from new tech: A newly cleared version of the company's heart-reading software is expected to save $100 million in costs over the next five years. The new algorithm should cut the time clinicians spend reviewing data by approximately 50% as it rolls out.
• Operating efficiency gains: Adjusted operating expenses fell slightly to $145.0 million compared to $145.2 million a year ago despite the higher volume of tests. This discipline helped the company report a much smaller net loss of just $0.4 million, compared to a $14.2 million loss last year.

Our take: This was a very strong quarter where the business proved it can grow quickly while also becoming much more profitable. The sharp jump in adjusted EBITDA margins to 19.3% and the raised full-year outlook show that the company is successfully scaling its costs. These results significantly strengthen the case for the business as it nears total profitability.